Total amount: € 0,00
HOW TO ORDER
A Journal on Internal Medicine
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6
Panminerva Medica 1999 March;41(1):22-6
Plasma endothelin-1 levels in patients with peripheral arterial occlusive disease at different Fontaine’s stages
Mangiafico R. A., Malatino L. S., Santonocito M., Sarnataro F., Dell’Arte S., Messina R., Santangelo B.
From the Institute of Internal Medicine “L. Condorelli”, University of Catania, Catania, Italy
Endothelin-1 (ET-1) is a potent vasoconstrictor and mitogenic peptide produced and secreted by endothelial cells, which can play a potential role in the development of atherosclerosis and in the pathophysiology of extreme vasoconstriction of various diseases.
Methods. To assess plasma endothelin-1 (ET-1) concentrations in patients with peripheral arterial occlusive disease (PAOD) at different Fontaine’s stages, we measured plasma ET-1 by radioimmunoassay in 14 stage II PAOD patients (12 men, 2 women; mean age 59.5±3.4 years) and in 10 stage III-IV PAOD patients (8 men, 2 women, mean age 61.2±3.3 years). Ten normal subjects (8 men, 2 women, mean age 58.1±7.2 years) were considered as controls.
Results. Mean (±SD) plasma ET-1 levels, as measured by radioimmunoassay, were significantly greater in stage II and stage III-IV PAOD patients than in control subjects (4±0.4 and 5±0.4 pmol/L vs 2.5±0.6 pmol/L, respectively, p<0.001). Furthermore, plasma levels of ET-1 in stage III-IV patients were significantly higher than in stage II patients (p<0.01). A significant correlation was found between plasma ET-1 levels and number of the arterial obstructive lesions in PAOD patients (r=0.698; p<0.0001). No significant correlation was found between plasma ET-1 concentrations and pain-free walking distance (r=-0.279, p=0.333, in stage II patients; r=0.137, p=0.705, in stage III-IV patients), and between plasma ET-1 levels and ankle/arm pressor index (r=0.032, p=0.913, in stage II patients; r=0.149, p=0.681, in stage III-IV patients) in the PAOD patients.
Conclusions. Raised plasma ET-1 could be a sensible marker both of endothelial damage and disease extension. It could also promote the progression of atherosclerotic plaques and enhance the microvascular resistance in these patients.